Search

In Stock

Buy Rilutek (riluzole) Online

DISEASE INDICATIONS: Amyotrophic Lateral Sclerosis (ALS)

MANUFACTURER: Sanofi – Aventis Groupe

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Therapeutic Goods Administration (TGA)

Medicines & Healthcare products Regulatory Agency (MHRA)

Medsafe (NZ)

Rilutek, also known by its generic name Riluzole, is a medication that has brought hope and relief to countless individuals facing the debilitating effects of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.

$211.07

Clear
Compare

Introduction

Rilutek, also known by its generic name Riluzole, is a medication that has brought hope and relief to countless individuals facing the debilitating effects of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. This description explores the history, mechanism of action, therapeutic uses, side effects, and ongoing research related to Rilutek.

I. History of Rilutek

Riluzole, developed by Sanofi-Aventis, received its first approval for the treatment of ALS in 1995 by the United States Food and Drug Administration (FDA). It marked a significant milestone in the quest for ALS management, as there was no known cure for this devastating disease at that time. Rilutek’s approval was followed by its introduction to the European and other international markets, providing hope to ALS patients worldwide.

II. Mechanism of Action

Rilutek’s mechanism of action in ALS remains a subject of ongoing research, but its primary function revolves around modulating the release of the neurotransmitter glutamate in the brain and spinal cord. In ALS, excessive glutamate release leads to the overstimulation of nerve cells, causing cell damage and ultimately cell death. Rilutek acts to reduce this glutamate-induced toxicity, potentially slowing down the progression of the disease.

III. Therapeutic Uses

  1. ALS Treatment: The primary and most well-known use of Rilutek is in the treatment of Amyotrophic Lateral Sclerosis. It is the first medication approved specifically for ALS therapy. By slowing down disease progression, Rilutek can extend the lifespan of individuals diagnosed with ALS, though its effects vary from patient to patient.
  2. Experimental Applications: Beyond ALS, Rilutek has been investigated for its potential use in other neurological conditions, such as Alzheimer’s disease, multiple sclerosis, and depression. These exploratory studies aim to harness the drug’s neuroprotective properties for broader therapeutic applications.

IV. Administration and Dosage

Rilutek is typically administered orally in the form of tablets. The standard recommended dosage for ALS patients is 50 milligrams twice daily, taken with or without food. It is crucial for patients to follow their healthcare provider’s instructions and not exceed the prescribed dose, as overdose can lead to adverse effects.

V. Side Effects

Like all medications, Rilutek comes with a range of potential side effects. It’s important for patients and healthcare providers to weigh the benefits against the risks when considering its use. Common side effects may include:

  1. Nausea
  2. Dizziness
  3. Abdominal pain
  4. Weakness
  5. Headache
  6. Increased liver enzyme levels

More severe, albeit less common, side effects may include:

  1. Allergic reactions
  2. Liver problems
  3. Blood disorders
  4. Lung problems

Patients are advised to report any unusual or severe side effects to their healthcare provider promptly. Regular monitoring of liver function is often recommended while taking Rilutek due to its potential impact on the liver.

VI. Ongoing Research and Future Directions

Despite being a valuable medication in the management of ALS, Rilutek is not a cure, and its effects vary among patients. Therefore, research continues to explore more effective treatments for ALS and other neurodegenerative diseases. Some promising areas of investigation include:

  1. Gene Therapies: Researchers are exploring gene therapies that aim to correct genetic mutations associated with familial ALS, potentially addressing the root causes of the disease.
  2. Stem Cell Therapies: Stem cell research holds promise for replacing damaged motor neurons in ALS patients, potentially reversing the damage caused by the disease.
  3. Neuroprotective Agents: Scientists are developing new neuroprotective agents that may prove more effective than Rilutek in slowing or halting the progression of ALS.
  4. Precision Medicine: Advancements in understanding the genetic and molecular underpinnings of ALS may lead to more targeted and personalized treatments.

VII. Conclusion

Rilutek, or Riluzole, has played a pivotal role in the fight against Amyotrophic Lateral Sclerosis since its approval nearly three decades ago. It represents a critical tool in the management of a disease that continues to challenge the medical community. While Rilutek’s mechanism of action and efficacy vary among individuals, it remains a beacon of hope for those affected by ALS, offering the possibility of extending their quality of life and time with loved ones. As research progresses, it is hoped that newer and more effective treatments will emerge, ultimately bringing us closer to a future without the devastating impact of ALS. Until then, Rilutek stands as a testament to the power of pharmaceutical innovation and the unyielding determination of medical science to combat the most complex and devastating diseases.

Package

50 mg x 56 tablets

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Mavenclad (cladribine) Online

From $1,840.67
(0 Reviews)
DISEASE INDICATIONS: Multiple Sclerosis MANUFACTURER: Merck Serono Europe Limited USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Mavenclad (cladribine) is a prescription medication that is used for the treatment of certain forms of multiple sclerosis (MS). It falls under the category of disease-modifying therapies (DMTs), which are designed to alter the course of the disease and reduce the frequency and severity of relapses in patients with MS.

Buy Fycompa (perampanel) Online

From $16.61
(0 Reviews)
DISEASE INDICATIONS: Epilepsy MANUFACTURER: Eisai Europe Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Fycompa (perampanel) is a prescription medication used in the treatment of epilepsy. It belongs to a class of drugs known as antiepileptic or anticonvulsant medications. Fycompa is specifically indicated for the management of partial-onset seizures with or without secondary generalized seizures in people with epilepsy.

Buy Calcort (deflazacort) Online

From $11.25
(0 Reviews)
DISEASE INDICATIONS: Duchenne Muscular Dystrophy MANUFACTURER: Merrell Dow/Henning USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA) Medicines & Healthcare products Regulatory Agency (MHRA) The Federal Institute for Drugs and Medical Devices (BfArM) Calcort (deflazacort) is a prescription medication classified as a glucocorticoid or corticosteroid. It is used to treat a variety of medical conditions that involve inflammation and immune system responses.

Buy Austedo (deutetrabenazine) Online

From $5,710.56
(0 Reviews)
DISEASE INDICATIONS: Huntington's Disease, Tardive Dyskenia MANUFACTURER: Teva Pharmaceuticals USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA) Austedo (deutetrabenazine) is a prescription medication used to manage certain movement disorders, primarily Huntington's disease and tardive dyskinesia, in adults.

Buy Edaravone (Daiichi Sankyo) Online

(0 Reviews)
DISEASE INDICATIONS: Amyotrophic Lateral Sclerosis (ALS), Cerebral Infarction MANUFACTURER: Daiichi Sankyo Company Limited USAGE: Intravenous MEDICINE APPROVED BY: Pharmaceuticals and Medical Devices Agency (PMDA) Edaravone is a medication developed and marketed by Daiichi Sankyo under the trade name Radicava. It is primarily used for the treatment of a specific neurological condition known as amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig's disease.

Buy Radicut (edaravone) Online

$944.97
(0 Reviews)
DISEASE INDICATIONS: Amyotrophic Lateral Sclerosis (ALS), Cerebral Infarction MANUFACTURER: Mitsubishi Tanabe Pharma Co., Ltd. USAGE: Intravenous MEDICINE APPROVED BY: Food and Drug Administration (FDA) Health Canada Pharmaceuticals and Medical Devices Agency (PMDA) Radicut, also known as Edaravone, is a prescription medication used in the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. This medication has garnered attention for its potential to slow down the progression of ALS, offering new hope to individuals living with this devastating condition.

Buy Aimovig (erenumab) Online

From $440.35
(0 Reviews)
DISEASE INDICATIONS: Migraine MANUFACTURER: Amgen Inc. / Novartis Pharmaceuticals Corporation USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Pharmaceuticals and Medical Devices Agency (PMDA) Therapeutic Goods Administration (TGA) Swissmedic (CH) Medsafe (NZ) Aimovig (erenumab) is a prescription medication used to treat certain types of migraine headaches in adults.

Back to Top
Product has been added to your cart